Brief: Bergenbio Announces Complete Data Analysis Of ACCORD2 Phase II Bemcentinib

Oncoinvent ASA

26/04/2022 06:12

April 26 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2
PHASE II
BEMCENTINIB
    * ANALYSIS CONFIRMS PRIMARY ENDPOINT OF IMPROVED CLINICAL
RESPONSE, KEY SECONDARY ENDPOINTS WERE MET
    * ENDPOINTS MET IN SUBPROTOCOL UNDER PLATFORM ACCORD2 STUDY
WHERE
BEMCENTINIB WAS ADDED TO STANDARD OF CARE THERAPY
    * LATEST RESULTS UNDERLINE BEMCENTINIB'S POTENTIAL IN
COVID-19 AND
OTHER SEVERE RESPIRATORY INFECTIONS
    * BEMCENTINIB TREATMENT WAS WELL TOLERATED IN THIS PATIENT
POPULATION, WITH NO CLINICALLY RELEVANT SAFETY SIGNALS IN
COMPARISON TO STANDARD OF CARE TREATMENT

Source text for Eikon:  ID:nObi1xqQCa 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))